Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | PTGIR | P43119 | 6/20 | 0.36 |
| ▸ | RORC | P51449 | 2/20 | 0.36 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6100304 | 0.81 | NISCH (0.49) | NISCHHTR1ATP53MEN1KMT2A | |
| SCHEMBL14367884 | 0.79 | NISCH (0.47) | NISCHHTR1ATP53MEN1KMT2A | |
| SCHEMBL6099692 | 0.78 | NISCH (0.46) | NISCHHTR1ATP53MEN1KMT2A | |
| SCHEMBL6102123 | 0.73 | NISCH (0.47) | NISCHHTR1A | |
| SCHEMBL6101300 | 0.71 | HTR1A (0.44) | NISCHHTR1AARPTGIRPTGDR | |
| SCHEMBL17443415 | 0.71 | NISCH (0.48) | NISCHMEN1KMT2ALMNARORC | |
| SCHEMBL4781055 | 0.71 | HTR1A (0.51) | HTR1ADRD2 | |
| SCHEMBL14367855 | 0.69 | PTGDR (0.45) | NISCHHTR1AARPTGIRPTGDR | |
| SCHEMBL14367872 | 0.69 | PTGDR (0.45) | NISCHHTR1AARPTGIRPTGDR | |
| SCHEMBL10249472 | 0.69 | MAOA (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060089353-A1 | Indole derivative compounds and drugs containing the compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-04-27 | — | — | US | disclosed |
| EP-1600440-A1 | INDOLE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089353-A1 | Indole derivative compounds and drugs containing the compounds as the active ingredient | PTGIS, IDO1, IDO2 | NISCH 2741/4885HTR1A 223/4885TP53 3795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.